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Eﬃcient striated muscle contraction requires precise assembly and regulation of diverse actin ﬁlament systems, most notably the
sarcomeric thin ﬁlaments of the contractile apparatus. By capping the pointed ends of actin ﬁlaments, tropomodulins (Tmods)
regulate actin ﬁlament assembly, lengths, and stability. Here, we explore the current understanding of the expression patterns,
localizations, and functions of Tmods in both cardiac and skeletal muscle. We ﬁrst describe the mechanisms by which Tmods
regulate myoﬁbril assembly and thin ﬁlament lengths, as well as the roles of closely related Tmod family variants, the leiomodins
(Lmods), in these processes. We also discuss emerging functions for Tmods in the sarcoplasmic reticulum. This paper provides
abundant evidence that Tmods are key structural regulators of striated muscle cytoarchitecture and physiology.
1.Introduction
Striated muscle cells are composed of densely packed
myoﬁbrils, which are, in turn, composed of large numbers of
sarcomeres that repeat in series. In sarcomeres, actin (thin)
ﬁlaments slide past myosin (thick) ﬁlaments to produce sar-
comere shortening and, thus, contractile force. The precise
temporalandspatialorchestrationofactinﬁlamentassembly
and architecture is critical for muscle contractile function
[1–3]. Notably, precise regulation of actin ﬁlament lengths
is a key feature of striated muscle sarcomeres and confers
muscle-speciﬁc biomechanical and contractile properties
(sarcomere length-tension relationships) [4–6]. Such ﬁnely
tuned actin assembly is made possible by the regulatory
actionsofactin-bindingproteins.Whileahostofproteinsare
known to nucleate ﬁlament assembly, cap the fast-growing
(barbed) ends of actin ﬁlaments, or bind along the sides of
ﬁlaments, only the tropomodulin (Tmod) family of proteins
caps the slow-growing (pointed) ﬁlament ends [7–12].
Tmods (∼40kDa) are present in all metazoans, including
ﬂies and worms [13–15], with four Tmod isoforms expressed
in mammalian cells; Tmod1 is predominantly expressed in
terminally diﬀerentiated, postmitotic cells (such as erythro-
cytes, lens ﬁber cells, neurons, and striated muscle), Tmod2
is in neuronal tissues, Tmod3 is nearly ubiquitous, and
Tmod4 is restricted to skeletal muscle ﬁbers [16–26]. Thus,
the Tmod isoforms relevant to actin ﬁlament regulation
in mammalian striated muscles are Tmod1, Tmod3, and
Tmod4. Tmods are dynamic caps that inhibit actin monomer
association and dissociation from actin ﬁlament pointed
ends [12, 27–30]; for a review, see [8]. Tmods also bind the
terminal tropomyosins (TMs) of TM-coated actin ﬁlaments,
and, through TM-isoform-speciﬁc binding [16–18, 31–39],
they regulate the tightness of actin ﬁlament pointed-end
capping and, thus, actin ﬁlament stability and lengths [12,
15, 19, 30, 36, 37, 40–42]; for reviews, see [1, 8, 43]. Aside
from their pointed-end capping activities, some Tmods also
possess actin monomer-binding and nucleation activities
[40, 44, 45]. In addition to Tmods, striated muscles also
contain leiomodin2 (Lmod2), a larger Tmod family variant
(∼65kDa) with a potent actin-nucleating activity that can
be regulated by TM [21, 46]. It is also noteworthy that the
closely related Lmod1, which is predominantly expressed
in smooth muscles, is additionally present in a subset of
extraocular striated muscle ﬁbers [47, 48].
The amino acid sequences of Tmods share ∼80%
similarity, and Tmods share a common domain structure2 Journal of Biomedicine and Biotechnology
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Figure 1: Schematic of the molecular sequence and domain organization of Tmods and Lmods found in vertebrate striated muscle. Tmods
contain an N-terminal TM-Cap domain and a C-terminal LRR-Cap domain, whose α-helices possess distinct combinations of TM-binding
and actin-regulatory activities, as shown. The α-helices are numbered sequentially within each domain, and the NES and NLS of Tmods
are highlighted. Lmods also contain a C-terminal extension with a polyproline region, two predicted α-helices, a basic region, and a WH2
domain.
with two major domains: an unstructured and extended N-
terminal half, the TM/pointed-end actin capping (TM-Cap)
domain,andacompactlyfoldedC-terminalhalf,theleucine-
rich repeat/pointed-end actin capping (LRR-Cap) domain
(Figure 1). The N-terminal TM-Cap domain is disordered
in solution [32, 49–51], except for one α-helix (residues
24–35), which provides the ﬁrst TM-binding site, and two
downstream predicted α-helices (residues 65–75 and 126–
135), which bind actin or provide the second TM-binding
site, respectively [22, 34, 36–39, 42, 45, 51–53] (Figure 1).
The C-terminal LRR-Cap domain of Tmods consists of a
series of ﬁve leucine-rich repeats (LRRs) that are composed
of tandem repeats of a parallel α-helix/β-sheet pair, followed
by a nonhomologous C-terminal α-helix (α6) and C-
terminal tail, which, together, provide an actin pointed-end
capping site [40, 54–56] (Figure 1). Tmod’s TM-Cap is the
unique TM-regulated actin pointed-end capping domain of
the Tmod family, with TM enhancing the capping activity
of the TM-Cap domain several thousand-fold [12, 30, 36–
38, 40, 42]. On the other hand, Tmod’s LRR-Cap domain
provides a unique actin pointed-end capping domain for
TM-free actin ﬁlaments [40, 54, 56]. The TM-Cap domain
can also bind actin monomers, and the TM-Cap and the
LRR-Cap domains are both required for actin nucleation
[44, 45]. These distinct actin-regulatory activities of the TM-
Cap and LRR-Cap domains and their constituent α-helices,
with respect to monomer-binding, ﬁlament capping, and
ﬁlamentnucleation[40,42,44,45](Figure1),impartTmods
withisoform-speciﬁcactin-regulatoryfunctions.Lmod1and
Lmod2 contain the α1- and α2-helices, but not the α3-helix,
of the TM-Cap domain, as well as the complete LRR-Cap
domain of Tmods, followed by a nonhomologous, ∼150-
residue-long C-terminal extension [21, 46]. This extension
contains a polyproline region, two predicted α-helices, a
basic region, and a WASP homology 2 (WH2) domain,
which, in Lmod2, imparts strong actin-nucleating activity
[46] (Figure 1).
Tmod family members play important roles in myoﬁbril
assembly and thin ﬁlament length regulation and are essen-
tial for striated muscle development and contractile function
in both vertebrates and invertebrates. Tmod1 (possibly in
combination with Lmod2 [46, 57, 58]) caps the pointed
ends of the sarcomeric thin ﬁlaments in cardiac muscle,
whereas a combination of Tmod1 and/or Tmod4 caps thin
ﬁlament pointed ends in skeletal muscle [11, 19, 31, 59–
62]( T a b l e1, Figures 2 and 3). The relative proportions
o fT m o d 1a n dT m o d 4i ns k e l e t a lm u s c l eh a v en o tb e e n
measured directly but may depend on the muscle twitch
speed, with Tmod4 predominating in fast skeletal muscle in
chickens [19]. By contrast, Tmod3 is normally not associated
with the sarcomeric thin ﬁlaments but, instead, appears to
cap and stabilize cytoplasmic (nonmuscle) γ-actin ﬁlaments
in the sarcoplasmic reticulum (SR) of skeletal muscle [63]
(Table 1, Figure 3). In mice, an SR-associated (or T-tubule)
compartment ﬂanking the Z-line also contains Tmod1 and
Tmod4 [63]. Tmod1 is also associated with costameric α2-
spectrin at the sarcolemma of fast chicken skeletal muscle
ﬁbers [19]( T a b l e1). Two recent reviews have discussed the
roles of Tmods in regulating actin dynamics in myoﬁbril
assembly and thin ﬁlament length regulation in some detail
[1, 64]. Therefore, in this paper, we will cover areas that have
not been previously discussed and emphasize new and recent
discoveries.
2. Tmods inMuscleDevelopment and
Myoﬁbril Assembly
Tmod1 is one of the earliest sarcomeric proteins expressed
during the development of cardiac and skeletal muscle,
matchingtheexpressionpatternsofthebasicstructuralcom-
ponents of sarcomeres. During mouse embryonic develop-
ment, Tmod1 mRNA and protein are ﬁrst detected at E8.0 in
thedevelopinghearttubeaswellasinthebloodislandsofthe
yolk sac [23, 59, 68], coinciding with sarcomeric α-actinin
and α-myosin heavy chain (α-MHC) expression [59, 65,
73]. Tmod1 persists throughout mouse heart development,
with expression especially high in the atrium and lower in
the ventricle at E15.5 in mid-gestation [65], similar to α-
MHC expression [73]. In chicken heart development, Tmod1
transcripts are expressed at Hamburger-Hamilton stage 11
in the looping heart tube, earlier than those of Lmod2 [58],
and Tmod1 protein is detected coordinately with cardiacJournal of Biomedicine and Biotechnology 3
Table 1: Expression and localization of Tmods and Lmods in striated muscle.
Protein Striated muscle expression Localization in striated muscle References
Tmod1 Cardiac and skeletal muscle
Thin ﬁlament pointed ends [11, 28, 31, 59, 60, 62, 65–67]
SR- or T-tubule-associated
compartment∗ [63]
Sarcolemma [19]
Tmod3 Cardiac and skeletal muscle SR∗∗ [63]
Tmod4 Skeletal muscle Thin ﬁlament pointed ends [19, 31]
SR- or T-tubule-associated
compartment [63]
Lmod1 Slow extraocular muscle ﬁbers A-band [47]
Lmod2 Cardiac muscle Thin ﬁlament pointed ends [46, 57, 58]
A-band [57]
∗To date, the putative SR-associated or T-tubule localization of Tmod1 has only been observed in skeletal muscle.
∗∗Tmod3 is expressed ubiquitously, including in cardiac muscle [20, 21], but Tmod3 expression levels and localization in mature cardiomyocytes are
uncertain, because Tmod3 is abundant in endothelial cells in all tissues [27].
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Figure 2: Immunoﬂuorescence localization of Tmods in skeletal muscle. Panels depict longitudinal cryosections of mouse tibialis anterior
muscle immunostained for (a) Tmod1, (b) Tmod3, or (c) Tmod4, phalloidin-stained for F-actin, and imaged by confocal microscopy,
preparedasin[31,63].NotethepredominantlocalizationofTmod1andTmod4atthepointedendsofthephalloidin-stainedthinﬁlaments.
Tmod1 and Tmod4 also exhibit Z-line-ﬂanking localizations, corresponding to an SR- or T-tubule-associated compartment. By contrast, the
M-line and Z-line-ﬂanking localization of Tmod3 is a signature of the SR [63]. Z, Z-line; M, M-line; P, thin ﬁlament pointed ends. Bars,
1μm.
actin and myosin in cardiomyocytes diﬀerentiating from
explants of precardiac mesoderm [74]. In mouse skeletal
muscle development, Tmod1 mRNA is ﬁrst detected in the
developingsomitesatE9.5,progressinginacaudal-to-rostral
fashion during embryonic development, resembling the
expressionpatternsofα-MHCandothersarcomericproteins
[23, 59]. By E14.5-15.5, Tmod1 mRNA and protein are
abundant in the developing skeletal muscles of the trunk and
limbs, as well as the diaphragm [23, 31]. In chickens, Tmod1
mRNA and protein are expressed in embryonic skeletal
muscle at 12 and 18 days of development, while Tmod4
mRNA and protein are not expressed in skeletal muscle
until after hatching [19]. The timing and patterns of Tmod3
and Tmod4 mRNA expression during mammalian muscle
development have not been investigated although Tmod3
and Tmod4 proteins are detected at E15.5 in developing
mouse hindlimb and back muscles [31]. Thus, in summary,
Tmod1 expression patterns are consistent with the notion
that Tmod1 is an integral structural component of the
sarcomericcontractilemachineryinbothcardiacandskeletal
muscle.
To understand how sarcomeric actin ﬁlament (thin
ﬁlament) assembly and lengths are coordinated with the
precisely orchestrated spatiotemporal assembly of myoﬁbril
components during development, Tmod1 assembly into
myoﬁbrils has been studied in the developing embryonic
mouse and chick heart and in cultured cardiomyocytes. In
the developing mouse heart, Tmod1 associates with nascent
myoﬁbrils containing nonstriated actin (i.e., with unreg-
ulated lengths) during initial stages of myoﬁbrillogenesis
and gradually becomes striated coordinately with actin, as
myoﬁbrils mature and precise thin ﬁlament lengths are spec-
iﬁed [59] (R. B. Nowak and V. M. Fowler, unpublished data).
This mirrors the results of experiments on cultured chick4 Journal of Biomedicine and Biotechnology
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Figure 3: Model diagram of Tmods in the sarcomeres and SR of skeletal muscle. Thin ﬁlaments, consisting of α-actin subunits, are capped
at their pointed ends by a combination of Tmod1 and Tmod4 in skeletal muscle, whereas Tmod3 is associated with cytoplasmic (nonmuscle)
γ-actin ﬁlaments in the SR. The exact stoichiometries and distributions of Tmod1 versus Tmod4 on the thin ﬁlament pointed ends are
unknown. Tmod-capped thin ﬁlaments extend past the distal N-terminus of nebulin into the middle of the sarcomere. By contrast, in
cardiac muscle (not shown here), thin ﬁlament pointed ends are capped solely by Tmod1 and do not contain nebulin. Filaments composed
of γ-actin, nonmuscle TMs, and Tmod3 are anchored to the SR membrane via sAnk1.5 and laterally connected by a spectrin network.
Tmod3/nonmuscle TM/γ-actin ﬁlaments are connected to myoﬁbrils via Tmod3 binding to sAnk1.5, which links to obscurin, which, in
turn, is linked to myomesin and titin at the M-line. To date, Tmod3’s localization with respect to the cardiac SR remains undetermined. Note
that for clarity, the thick ﬁlaments are not drawn to scale with respect to the thin ﬁlaments.
skeletal myotubes, in which Tmod1 assembles into puncta
in nascent myoﬁbrils in lamellipodial extensions containing
nonstriated actin early in myoﬁbrillogenesis and gradually
becomes striated along with actin as myoﬁbrils mature [61].
By contrast, in whole-mount preparations of embryonic
chicken hearts, in chick cardiac mesoderm explants, and in
developing axolotl hearts, Tmod1 localizes to puncta at the
cell membrane, where myoﬁbril assembly is initiated early
in development, but as myoﬁbrillogenesis nears completion
later in development, thin ﬁlaments appear to become
striated (i.e., length-regulated) prior to capping by Tmod1
[66, 67, 74]. Similarly, in embryonic chick cardiomyocyte
cultures, Tmod1 assembles onto thin ﬁlaments after TM and
all other major sarcomeric proteins have assembled, and
after actin becomes striated, suggesting that Tmod1 capping
is not required for thin ﬁlament length regulation during
myoﬁbril assembly [60]. These diﬀerences in the timing of
Tmod1 assembly are not explained by variations in Tmod
isoforms, because Tmod1 caps the thin ﬁlament pointed
ends in all of these systems [19, 59, 61, 66, 67, 74]. Instead,
alterations in Tmod1 conformation and epitope accessibility
at various stages of myoﬁbril assembly may play a role,
because a Tmod1 polyclonal antibody or a Tmod1 mono-
clonal antibody (mAb95) detects Tmod1 in nonstriated actin
structuresatthemembraneandinmaturestriatedmyoﬁbrils
in embryonic chicken hearts, skeletal myotubes, and axolotl
hearts [61, 66, 67, 74], whereas another antibody, mAb9,
did not detect any Tmod1 associated with nonstriated actin
structures near cell membranes in either chick or axolotl
hearts [66, 67]. Since mAb9 binds to the actin-capping site
in the LRR-Cap domain of Tmod1 [28, 40], Tmod1’s actin-
capping activity at thin ﬁlament pointed ends may vary
during myoﬁbril assembly, thus masking or revealing this
epitope. Based on these studies, Tmod1 may have an early
function in regulating actin pointed-end dynamics in the
initial stages of myoﬁbril assembly at the membrane and a
later function in maintaining thin ﬁlament lengths in mature
myoﬁbrils [60, 65, 66].Journal of Biomedicine and Biotechnology 5
Table 2: Summary of myoﬁbril assembly and thin ﬁlament length phenotypes in Tmod1 perturbation experiments.
Perturbation Model system Experimental strategy Resulting phenotype References
Reduced Tmod1 levels
Mouse embryonic heart Gene knockout Myoﬁbril disorganization,
nonstriated actin [59, 65, 68]
Mouse embryonic stem
cells Gene knockout Myoﬁbril disorganization,
nonstriated actin [69]
Mouse skeletal muscle Gene knockout No eﬀect∗ [31]
Rat cardiomyocytes Antisense cDNA expression Thin ﬁlament elongation,
nonstriated actin [70]
Drosophila primary muscle
cells∗∗ RNAi knockdown
Sarcomere length
irregularity, thin ﬁlament
elongation
[71]
C. elegans body wall
muscle∗∗∗
RNAi knockdown,
unc94/tmd-1 mutant alleles
Myoﬁbril disorganization,
nonstriated actin, myoﬁbril
attachment defects
[14, 15]
Inhibition of Tmod1
function
Chick cardiomyocytes Antibody inhibition of
actin capping
Thin ﬁlament elongation,
nonstriated actin [28]
Chick cardiomyocytes Antibody inhibition of TM
binding Thin ﬁlament disassembly [41]
Tmod1 overexpression
Chick cardiomyocytes cDNA expression Thin ﬁlament shortening [29]
Rat cardiomyocytes cDNA expression Myoﬁbril disorganization,
thin ﬁlament shortening [70]
Adult mouse heart
α-Myosin heavy chain
promoter-driven Tmod1
transgene
Myoﬁbril disorganization,
thin ﬁlament shortening,
intercalated disc defects
[72]
Drosophila indirect ﬂight
muscle∗∗
HSP-90-driven Tmod
transgene Thin ﬁlament shortening [13]
Drosophila primary muscle
cells∗∗
Dmef-GAL4, UAS-Tmod
transgene Thin ﬁlament shortening [71]
∗NomyoﬁbrilassemblyorthinﬁlamentlengthalterationsoccurinTmod1-nullmouseskeletalmuscle,butextrasarcomericSRdefectsdooccurduetoTmod3
translocation from the SR to the thin ﬁlament pointed ends.
∗∗Drosophila Tmod was knocked down or overexpressed.
∗∗∗C. elegans UNC94/TMD-1 was knocked down or overexpressed.
An essential requirement for Tmod1 in cardiac devel-
opment and myoﬁbril assembly is demonstrated by the
phenotype of Tmod1-null mice [59, 68]( T a b l e2). Deletion
of Tmod1 is embryonic-lethal, with Tmod1-null embryos
appearingmorphologicallynormalthroughE7.5butexhibit-
ing defects in cardiac looping morphogenesis, chamber
formation, and myoﬁbrillogenesis by E8.5, which result in
aborted establishment of the circulation and death by E9.5-
10.5 [59, 65, 68]. The primary defect of Tmod1-null mice is
in the myocardium, because cardiomyocyte-speciﬁc expres-
sion of Tmod1, via a Tmod1 transgene expressed using an α-
MHC promoter, can completely reverse essentially all of the
pathologicalphenotypesobservedintheTmod1-nullmouse,
including the cardiac looping defect, aberrant myoﬁbril
assembly, defects in yolk sac vasculogenesis, and embryonic
lethality [65]. In the absence of Tmod1, myoﬁbrils in the
developing mouse heart are unable to mature from primitive
I-Z-Ibodieswithnonstriatedactin,resultinginincompletely
assembled thin ﬁlaments and impaired contractility [59, 65,
68].However,theseresultsaredistinctfromaninvitromodel
of myoﬁbril assembly in cardiomyocytes diﬀerentiating
from mouse embryonic stem cells in Tmod1-null embryoid
bodies, where occasional thin and wispy myoﬁbrils do
assemble with regulated thin ﬁlament lengths [69]. Similar
to the Tmod1-null embryonic heart, contractility is also
impaired in this in vitro model, due to reduced numbers and
defective maturation of myoﬁbrils and cardiomyocytes [69].
The unexpected presence of some myoﬁbrils with regulated
thin ﬁlament lengths in absence of Tmod1 is unlikely to
be due to compensation by Tmod4, since Tmod4 mRNA
is not expressed in the embryonic stem cells or embryoid
bodies [69]. However, Tmod3 mRNA is present, and while
Tmod3 mRNA levels are unchanged upon deletion of Tmod1
[69], Tmod3 protein may have assembled onto the thin
ﬁlamentpointedends,structurallycompensatingforabsence
of Tmod1, similar to compensation by Tmod3 protein in
Tmod1-null skeletal muscles [31].
In contrast to cardiac muscle, deletion of Tmod1 from
m o u s es k e l e t a lm u s c l ed o e sn o ta p p e a rt oa ﬀect skeletal mus-
cle development or myoﬁbril assembly in vivo [31]( T a b l e2).
This is most likely due to the additional presence of Tmod4
at the thin ﬁlament pointed ends, which may protect embry-
onic skeletal muscles from the myoﬁbril assembly defects
observed in Tmod1-deﬁcient cardiac myoﬁbrils (Figures 26 Journal of Biomedicine and Biotechnology
and 3). In addition, in adult Tmod1-null muscles, Tmod3
translocates from extrasarcomeric sites to cap thin ﬁlament
pointed ends together with Tmod4, thus maintaining correct
thin ﬁlament lengths and sarcomere structure, structurally
compensating for the absence of Tmod1 as skeletal muscle
matures [31, 63]. Taken together, these studies indicate
that, in mice, complete removal of pointed-end capping
by Tmods severely disrupts both muscle development and
myoﬁbril assembly (in cardiac muscle), but partial removal
has no obvious eﬀects (in skeletal muscle). The minimum
stoichiometry of Tmods that are required to sustain the
normal developmental program and myoﬁbrillogenesis in
skeletal muscle remains unclear.
An intriguing question raised by these studies is the
relationship between Tmod1’s role in myoﬁbril assembly and
Tmod1’s role in muscle development [31, 59, 65, 68, 69].
Namely, is Tmod1’s primary role to regulate myoﬁbrillogen-
esis, with defects in cardiac looping and chamber formation
inTmod1-nullheartsassecondaryconsequencesofimpaired
contractility? Alternatively, could Tmod1 also function in an
independent pathway to regulate cardiac morphogenesis and
development? Interestingly, Tmod1 is traﬃcked through the
nucleus in cultured skeletal myocytes and cardiomyocytes,
as well as ﬁbroblasts, and Tmod1, Tmod2, and Tmod3
all contain a pattern-4 nuclear localization signal (NLS;
residues 340–343 of Tmod1; Figure 1), whereas Tmod4
and the Drosophila Tmod homologue contain arginine-
and lysine-containing motifs that are similar to pattern-
4N L S s[ 75]. Similarly, Tmod1 contains a nuclear export
signal(NES;residues134–136;Figure1)that,whenmutated,
results in Tmod1 accumulation in the nucleus [75]. Tmod1
accumulation in the nuclei of diﬀerentiating C2C12 mouse
myoblasts results in depressed expression of muscle-speciﬁc
genes and delayed myogenic diﬀerentiation in vitro [75].
Tmod1’s NES is contained within the TM-binding α3-helix
(Figure 1), and mutation of these residues to eliminate
TM binding leads to nuclear accumulation of Tmod1,
indicating that the TM-binding and nuclear export activities
of Tmod1 may function coordinately [52, 75]. Tmod1 may
also inﬂuence muscle development via Tmod1 capping and
stabilization of TM-actin ﬁlaments, thereby depleting the
actin monomer pool and regulating muscle gene expression
via the actin/myocardin-related transcription factor/serum
response factor circuitry [76].
Recent studies of Tmod function in invertebrates pro-
vide clues to a network of actin regulatory proteins that
orchestrate actin ﬁlament organization in myoﬁbril assem-
bly and control thin ﬁlament lengths in sarcomeres [64]
(Table 2). In the obliquely striated body-wall muscle of C.
elegans, mutation or RNAi depletion of the Tmod homolog
UNC94/TMD-1 leads to severe actin ﬁlament disorganiza-
tion of actin ﬁlament bundles with accumulation near cell-
cell boundaries and impaired motility [14, 15]. In addition,
defects are also observed in the organization of muscle dense
bodies, the myoﬁbril attachment sites at the membrane
[14]. The actin organization and myoﬁbril assembly defects
in unc94/tmd-1 mutants are strikingly similar to those
observed in C. elegans mutants for actin-depolymerizing
factor (ADF)/coﬁlin, actin-interacting protein 1, and pro-
ﬁlin, which also regulate sarcomeric actin ﬁlament assembly
and stability [15, 77–79]. ADF/coﬁlin enhances dissociation
of actin subunits from the pointed end [80], while TMD-
1 inhibits ADF/coﬁlin-induced actin depolymerization by
a TM-dependent pointed-end capping mechanism in vitro
[15]. These biochemical interactions imply that TMD-1
would be antagonistic to ADF/coﬁlin function in vivo.
However, unexpectedly, TMD-1 cooperates synergistically
with ADF/coﬁlin to control sarcomeric actin organization
and motility, with double mutants more severely aﬀected
than single mutants [15]. These in vivo genetic interac-
tions could be explained if, in muscle cells, TMD-1 and
ADF/coﬁlin both prevent excessive actin elongation at the
thin ﬁlament pointed end by TMD-1 capping the pointed
end and ADF/coﬁlin inducing pointed-end disassembly. The
identiﬁcation of coﬁlin2 gene mutations in patients with
nemaline myopathy, a skeletal muscle disease characterized
by accumulations of aberrant actin ﬁlament bundles and
muscle weakness [81], suggests conserved mechanisms to
regulate sarcomeric actin assembly and organization that
may also involve Tmods [15]; for reviews, see [1, 64].
3. Tmods and Thin Filament Length Regulation
in StriatedMuscle Sarcomeres
Once thin ﬁlaments are assembled into sarcomeres and
myoﬁbrils during muscle development, Tmods function to
regulate thin ﬁlament lengths by controlling actin ﬁlament
elongation and shortening at pointed ends [1]( T a b l e2).
In cardiac myoﬁbrils, where thin ﬁlament pointed ends
are capped by Tmod1, actin dynamics and thin ﬁlament
lengths are inversely proportional to Tmod1 levels [29,
70]. This was observed directly in experiments in which
rhodamine-labeledskeletalmuscleα-actin(rho-α-actin)was
microinjected into living chick cardiomyocytes, allowing
direct visualization of actin monomer incorporation at both
the barbed and pointed ends [29]. Inhibition of actin
dynamics at the barbed and pointed ends has distinct eﬀects:
overexpression of GFP-Tmod1 reduces actin incorporation
at pointed ends and leads to thin ﬁlament shortening, but
cytochalasin D inhibition of barbed-end dynamics has no
eﬀect on lengths [29]. Furthermore, microinjection of an
antibody that inhibits Tmod1’s actin pointed-end capping
activity by binding to the actin capping site in the C-terminal
α6-helix of the LRR-Cap [28, 40] results in elongation of
thin ﬁlaments from their pointed ends and inhibition of
cardiomyocyte beating [28]. Thus, while actin monomer
exchange occurs at both barbed and pointed ends in striated
muscle sarcomeres, only subunit exchange at pointed ends
directly determines thin ﬁlament length. Moreover, both
rho-α-actin microinjection into cardiomyocytes [29]a n d
GFP-α-actin expression in living mouse skeletal muscle [82]
revealed preferential incorporation at thin ﬁlament pointed
ends, indicating that the pointed ends are more dynamic
than the barbed ends. The interaction between Tmod1 and
cardiac TM is essential for thin ﬁlament length regulation by
Tmod1; monoclonal antibody inhibition of the TM-bindingJournal of Biomedicine and Biotechnology 7
site in the TM-Cap α1-helix causes Tmod1 dissociation and
thin ﬁlament depolymerization from the pointed end [41].
Indeed, Tmod1 targeting to pointed ends in cardiomyocytes
depends on prior assembly of TM [60] and on both the α1-
and α3-helices in the TM-Cap domain [56]. Thus, actin,
Tmod1, and TM synergize to maintain thin ﬁlament lengths
in cardiomyocytes.
While cultured cardiomyocytes provide a useful system
to study Tmod targeting to thin ﬁlament pointed ends and
length regulation, they provide less insight into the phys-
iological ramiﬁcations of altered thin ﬁlament regulation
whenTmod1levelsareperturbed.α-MHC-driventransgenic
overexpression of Tmod1 in the in vivo mouse heart leads
to shorter thin ﬁlaments, consistent with increased pointed-
end capping in these hearts [72]( T a b l e2). Mice with
Tmod1-overexpressing hearts develop a dilated cardiomy-
opathy between P14 and P28, which occurs concomitantly
with a loss of myoﬁbrillar organization, featuring defects
that reﬂect the in vitro scenario with striking similarity
[70, 72]. The onset of dilation does not appear to alter
the extent of Tmod1 overexpression, indicating that these
processes are not directly coupled to one another, but rather,
overexpression of Tmod1 appears to trigger a cascade of
compensatory responses, including myocardial remodeling,
changes in intercalated discs, and myocardial Ca2+ handling
that lead to dilated cardiomyopathy [83–88].
The notion that the extent of pointed-end capping by
Tmods is inversely proportional to thin ﬁlament length is
not unique to cardiomyocytes and is supported by studies
in Drosophila melanogaster indirect ﬂight muscle (Table 2).
TransientoverexpressionofDrosophilaTmodduringindirect
ﬂight muscle development via the HSP-90 promoter inhibits
actinelongationfromthinﬁlamentpointedendsandreduces
thin ﬁlament lengths [13]. Note that the Drosophila Tmod
gene was originally misidentiﬁed as responsible for the
Sanpodo (spdo) asymmetric cell division phenotype [89,
90], but spdo was later determined to be a tetraspanin
membrane protein in the Notch signaling pathway [90–
92]. Thin ﬁlament lengths in Drosophila are also regulated
by sarcomere length short (SALS), a Drosophila WH2-
domain-containing protein that is required for GFP-actin
incorporation at pointed ends and thin ﬁlament elongation
during myoﬁbril assembly in developing larval muscles [71].
Genetic manipulation of SALS and Tmod levels in primary
embryonic muscle cells revealed that SALS promotes the
lengthening of thin ﬁlaments by antagonizing the pointed-
end capping activity of Tmod [71], analogous to a proposed
function of Lmod2 in cardiomyocytes (see Section 5)[ 58],
which do not contain the insect-speciﬁc SALS protein [71].
However, similar to Tmod, SALS appears to cap actin
ﬁlament pointed ends in vitro, which is puzzling based on
its in vivo function in promoting pointed-end elongation
[71]. Further biochemical studies are required to clarify
cooperativeand/orcompetitive actinregulationbySALSand
Tmod. Presumably, Drosophila indirect ﬂight muscle cells are
programmed to maintain a balance between SALS and Tmod
to optimize thin ﬁlament lengths in a manner that promotes
muscle contraction and ﬂight, as ﬂies with excess Tmod and
shortened thin ﬁlaments are unable to ﬂy [13].
In the case of myoﬁbrils in mammalian skeletal muscle,
thin ﬁlament length regulation is further complicated by
the presence of a combination of Tmod isoforms (Tmod1
and Tmod4) at the pointed ends [11, 19, 31] (Figures 2
and 3). Partially depleting the Tmod isoform inventory
of skeletal muscle by deleting Tmod1 does not alter thin
ﬁlament lengths in vivo, presumably because Tmod3 can
structurallysubstitutefortheabsenceofTmod1byleavingits
SR compartment (see Section 6) to cap thin ﬁlament pointed
ends in conjunction with Tmod4 [31, 63]. The switch
from Tmod1/Tmod4-based capping to Tmod3/Tmod4-based
capping of thin ﬁlament pointed ends produces physio-
logical changes despite unchanged thin ﬁlament lengths;
these changes include depressed isometric stress production,
impaired locomotor activity, and ﬁber type reprogramming
toward a faster phenotype [31]. Given that this Tmod1-null
skeletal muscle phenotype is distinct from the more striking
thin ﬁlament length misregulation phenotypes observed as
a consequence of Tmod1 perturbations in cardiac muscle
(Table 2), the minimum Tmod isoform types and levels
that are required to maintain correct thin ﬁlament lengths
in skeletal muscle sarcomeres remain unclear. Indeed, the
stoichiometry of Tmods at thin ﬁlament pointed ends in
rat psoas skeletal muscle, which likely contains Tmod1 and
Tmod4 [11, 20, 21, 31] (V. M. Fowler, unpublished data), has
been determined to be between 1.2–1.6Tmods/pointed end,
based on quantitative immunoprecipitation using Tmod1
antibodies [11], but this may have been an underestimate
due to antibody cross-reactivity with Tmod4 in the absence
ofpriorcross-adsorption[31].Tofullyaddressthisquandary
in vivo, Tmod1 and Tmod4 isoform stoichiometries at
thin ﬁlament pointed ends need to be measured for var-
ious skeletal muscles, and Tmod3-null, Tmod4-null, and
Tmod1/Tmod3/Tmod4-double- and triple-null mice need to
be developed for future studies.
4. Tmod/Nebulin Interactionsand
Thin FilamentLength Regulation in
Skeletal Muscle
In addition to being capped by both Tmod1 and Tmod4,
skeletal muscle thin ﬁlaments are also distinct from cardiac
thin ﬁlaments because they contain giant (∼600–900kDa)
nebulin molecules that coextend with actin along their
lengths (Figure 3). Several recent reviews have discussed
the roles of nebulin in thin ﬁlament length regulation and
actomyosin crossbridge activity [93–96], but, here, we will
focus on aspects of nebulin relevant to Tmods. Nebulin’s N-
terminal domain is located near thin ﬁlament pointed ends
and contains an interaction site for Tmods [97], while nebu-
lin’s C-terminal domain is located at the barbed ﬁlament end
in the Z-line, containing an interaction site for CapZ [98,
99]. Tmod1, Tmod4, and the C-terminal LRR-Cap domain
of Tmod1 bind to an N-terminal module (M1M2M3) of
nebulin in vitro, based on solid-phase ELISA-binding assays
with nebulin fragments and blot overlay assays with full-
lengthnebulin[54,97].BindingofnativenebulinandTmods
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demonstrated in blot overlay assays, but this interaction is
weak [97, 100]. Tmod4 binds to nebulin more strongly than
Tmod1, and TM does not appear to aﬀect the interaction
between Tmods and nebulin [97]. However, the eﬀect of
the nebulin M1M2M3 module on Tmod’s ability to cap the
pointed ends of TM-coated or TM-free actin ﬁlaments has
not been investigated in vitro.
Previous models of nebulin’s layout within the thin
ﬁlament have asserted that nebulin is a “molecular ruler”
that orchestrates thin ﬁlament assembly and lengths. The
ruler hypothesis argues that nebulin speciﬁes the number
of actin monomers that can polymerize and ﬁll the space
between its C-terminal CapZ-binding site and its N-terminal
Tmod-binding M1M2M3 module, which would presumably
localize to their respective thin ﬁlament ends [1, 3, 93,
101, 102]. Such an arrangement predicts that shorter or
longer nebulin splice variants [103–105] produce shorter
or longer thin ﬁlaments, respectively, and account for the
correlation between nebulin isoform size and thin ﬁlament
length [106, 107]. However, surprisingly, recent data have
demonstrated instead that the nebulin M1M2M3 module is
located only ∼0.9-1.0μm away from the Z-line in all mature
mammalian muscles studied, whereas the thin ﬁlament
pointed ends extend from ∼0.1μmu pt o∼0.4μm further
from the Z-line, well past the nebulin M2M3M3 module
[1, 31, 108] (Figure 3). Moreover, despite the interactions
between Tmods and the nebulin M1M2M3 module in vitro,
Tmod1 and Tmod4 are located at the extreme pointed ends
of the thin ﬁlaments and do not colocalize with the nebulin
M1M2M3 module in mature mouse, rabbit, and chicken
muscles [31, 108], as well as in human muscles (D. S. Gokhin
and V. M. Fowler, unpublished data). Thus, Tmods likely do
not interact with nebulin in mature mammalian muscles in
vivo [31, 108]. Furthermore, in neonatal nebulin-null mice,
Tmod1 is correctly localized to the pointed ends of the thin
ﬁlaments, whose lengths are now uniformly ∼1.0μm, up
to ∼30% shorter than in wild-type muscles (as determined
by Tmod1 localization and phalloidin staining) [109]. Thin
ﬁlamentlengthsintheabsenceofnebulinareidenticalacross
all muscles and, curiously, are similar to the distance at
which the nebulin M1M2M3 module normally resides with
respect to the Z-line [31, 108]. In addition, thin ﬁlaments
in nebulin-null mouse skeletal muscles appear to partially
degenerate during muscle use as the mice develop, until
lethality occurs between P7 and P21 [99, 109], explaining
the broad Tmod localization observed across the I-bands
at P10 [6]. Irregular thin ﬁlament disassembly during
muscle development or use may also explain the broad
Tmod localization pattern associated with the nonuniform
and shorter ﬁlament lengths in the muscles of human
nemaline myopathy patients that contain reduced nebulin
levels [6]. Likewise, thin ﬁlaments in nebulin siRNA-treated
chick skeletal myotubes are unusually prone to latrunculin
A-induced actin depolymerization [110]. Based on these
observations, nebulin appears to both mechanically and
molecularly stabilize a large, ∼1.0-μm-long core region of
the thin ﬁlament, whose length deﬁnes the minimum thin
ﬁlament length that a skeletal muscle sarcomere can stably
maintain.Inconjunction,actindynamicsatthethinﬁlament
pointedends(regulatedbyTmod1andTmod4)areproposed
to specify the lengths of the nebulin-free, ∼0.1 to ∼0.4-
μm-long thin ﬁlament extensions beyond the M1M2M3
module of nebulin [1, 29, 31, 108, 110]. However, the actin
dynamics properties and actomyosin crossbridge-regulatory
characteristics of these nebulin-free extensions (compared to
those of the “canonical” nebulin-coated thin ﬁlament cores)
have not been studied directly.
It remains uncertain how the nebulin M1M2M3 module,
or other nebulin modules, could regulate Tmod-mediated
capping “at a distance” in order to specify precise muscle-
speciﬁc thin ﬁlament lengths determined by the variable
lengths of the nebulin-free thin ﬁlament extensions [1,
31, 108]. This conundrum is highlighted by an elegant
recent experiment in chick skeletal myotubes, in which
endogenous nebulin was replaced by a shorter mininebulin
containing the N- and C-termini of human nebulin but
lacking 18 (out of 22) central superrepeats [110]. Even in
the presence of mininebulin, the thin ﬁlaments still extended
well past the N-terminal end of mininebulin and were
capped by Tmod1 at their normal location in the center of
the sarcomere [110]. Nevertheless, the dynamics of GFP-
α-actin, GFP-Tmod1, and GFP-TM were enhanced in the
absence of nebulin, and dynamics were reduced (rescued)
by introducing mininebulin, as measured by ﬂuorescence
recovery after photobleaching (FRAP). This suggests that
nebulin may alter the long-range conformation of the TM
polymer and/or actin molecules in the thin ﬁlament, thereby
indirectly stabilizing Tmod capping of actin and TM at the
pointed end some distance away from the nebulin molecule
itself [110]. The maximum distance from which nebulin
can aﬀect Tmod dynamics remains elusive, but it is most
likely on the order of ∼0.3-0.4μm, which is the longest thin
ﬁlament pointed-end extension measured to date [108]( D .
S. Gokhin and V. M. Fowler, unpublished data). It is also
possible that the nebulin M1M2M3 module may interact
directly with Tmod at as-yet-unidentiﬁed developmental
junctures or during the early stages of myoﬁbril assembly
when thin ﬁlaments may be shorter [61, 111, 112]. Thus,
in skeletal muscle, thin ﬁlament lengths are likely regulated
in a complex fashion by the dynamic properties of Tmods,
nebulin, actin, and TM in combination. Heterogeneous
expression of thin ﬁlament-associated protein isoforms may
determine muscle-speciﬁc thin ﬁlament lengths that are
essential for specifying muscle-speciﬁc sarcomere length-
tension relationships for joint motion and mammalian
motility [4–6].
5. Lmods in Actin Nucleation,
Thin FilamentAssembly, and
Length Regulation
A plethora of actin nucleators have been identiﬁed in
nonmuscle cells that promote assembly of actin ﬁlaments
intolamellipodia,ﬁlopodia,orstressﬁbersviaactinassembly
atbarbedﬁlamentends[113].Instriatedmuscle,theformin-
homology-domain protein FHOD3 regulates actin assembly
and myoﬁbril integrity in rat cardiomyocytes [114, 115],Journal of Biomedicine and Biotechnology 9
while the C-terminal SH3 domain of nebulin activated by
N-WASP promotes de novo assembly of thin ﬁlaments at
Z-lines during sarcomerogenesis [116]. The larger Tmod
family member, Lmod2, which is localized to stripes ﬂanking
the M-line in cultured cardiomyocytes [46, 57, 58], also
exhibits a potent actin nucleating activity in vitro, which
is enhanced by TM [46]. In rat cardiomyocytes, siRNA
knockdown of Lmod2 results in defective myoﬁbril assembly
with disorganized, thin, and wispy myoﬁbrils, implicating
Lmod2 in the assembly of thin ﬁlaments and myoﬁbrils [46].
Based on the in vitro properties of Lmod2, de novo Lmod2-
nucleated ﬁlaments assembling into sarcomeres could grow
from their barbed ends with Lmod2 remaining at their
pointed ends [46, 57, 58]. However, this mechanism would
be somewhat surprising, since previous studies have shown
thatthin ﬁlamentsin sarcomereselongatefromtheir pointed
ends (see Section 3)[ 13, 29, 71]. In agreement with
the latter, overexpression of Lmod2 in embryonic chick
cardiomyocytes displaced Tmod1 from pointed ends and
led to thin ﬁlament lengthening [58]. By analogy to SALS
function in Drosophila myocytes (see Section 3)[ 71], Lmod2
has been proposed to “ﬁne-tune” thin ﬁlament lengths in
mature cardiomyocyte sarcomeres by competing with and
antagonizing the activity of Tmod1 at the thin ﬁlament
pointed ends [58]. Alternatively, since the Lmod2 WH2
nucleationdomainisrequiredforthinﬁlamentelongationin
this system [58], it is possible that this ﬁlament lengthening
could be due to de novo nucleation and elongation of
new ﬁlaments that are then incorporated into existing
sarcomeres. Testing these models and integrating Lmod2
functions with those of the FHOD3 and nebulin-SH3 actin
nucleators will require the determination of the sites of
actin incorporation and ﬁlament elongation during thin
ﬁlamentassemblyandturnoverduringmyoﬁbrillogenesis,as
compared to myoﬁbril maturation and maintenance during
muscle contraction and adaptation in vivo.
Lmod2hasalsobeensuggestedtoplayaroleinregulating
actomyosin contractility in mature sarcomeres. In neonatal
rat cardiomyocytes, Lmod2 colocalizes with myosin in the A-
band (i.e., in broad stripes ﬂanking Tmod1 at the pointed
ends) [57]. This A-band localization of Lmod2 was only
observed in mature myoﬁbrils and depended on myosin
activity as well as on the availability of free actin monomers
[57]. Indeed, the myoﬁbril disruption observed upon siRNA
knockdownofLmod2[46]couldpotentiallybeduetoeﬀects
on myosin activity, which inﬂuences myoﬁbril assembly
and organization under some conditions [57, 117–120].
The relationship of the A-band localization of Lmod2 in
rat cardiomyocytes [57] to the pointed-end localization of
Lmod2 in embryonic chick cardiomyocytes [58] is unclear,
since full-length Lmod2 is a strong actin nucleator that
produces barbed-end elongation in vitro and does not cap
actin ﬁlament pointed ends [46, 57, 58]. However, truncated
Lmod2 missing the WH2 domain caps pointed ends in a
TM-dependent manner [58], suggesting that additional reg-
ulatory factors that inhibit nucleation activity may convert
Lmod2 to pointed-end capping in cells. Further studies will
be required to determine whether the disparate localizations
reported in diﬀerent studies are due to Lmod isoform or
species diﬀerences or diﬀerences in myoﬁbril maturation in
rat as opposed to chicken cardiomyocytes. Additional work
will also be required to resolve the reported discrepancies in
Lmod2 functions, including knockout models for Lmods to
determine in vivo functions.
Considerably less is known about Lmod1, which is
predominantly expressed in smooth muscle cells, in which
thinﬁlamentlengthsarenotpreciselyregulatedoraligned.In
hypercontracted smooth muscle, which reveals a subdomain
organization of α-actinin-containing dense bodies alternat-
ingwithactinﬁlament-richregions,bothLmod1andTmod1
are concentrated in the actin ﬁlament-rich regions between
the dense bodies [48]. This suggests that Lmod1 and Tmod1
may be associated with the pointed ends of variable-length
smooth muscle thin ﬁlaments extending from the dense
bodies. However, in extraocular striated muscle, Lmod1
colocalizes with the typical myosin-staining doublet in the
A-bands of slow muscle ﬁbers [47], similar to Lmod2 in
rat cardiomyocytes [57]. This contrasts with Tmod1, which
localizes to a single stripe in the middle of the sarcomere
in these unstretched muscles, as expected from the close
proximity of the locations of the thin ﬁlament pointed ends
from each half-sarcomere [47, 48]. This suggests that, unlike
Tmod1, which caps the thin ﬁlament pointed ends, Lmod1
may interact with the regions of thin ﬁlaments that interact
with myosin in the A-band, or Lmod1 may possibly bind
directly to myosin. Lmod1 binds striated muscle TM in vitro
[48],butitsfunctionhasotherwisenotbeenstudied.(Athird
Lmod gene, Lmod3, has been identiﬁed (human gene ID,
56203; mRNA, NM 198271), but its protein localization and
function remain unknown).
6. Tmods andthe SR
The SR is a membrane system that wraps around myoﬁbrils
and serves as the Ca2+ reservoir for muscle contraction.
The skeletal muscle SR contains an actin ﬁlament network
composed of cytoplasmic γ-actin (in contrast to myoﬁbrils,
which contain skeletal muscle α-actin) [63]. γ-Actin is
thought to be involved in the compensatory remodeling
response of skeletal muscle to muscular dystrophy, based
on its dramatic upregulation in diverse animal models of
the disease [121, 122]. While the ﬁlament-level architecture
of the γ-actin network is unknown, it likely shares features
withTmod-cappedactinﬁlamentarchitecturesinnonmuscle
cells, such as epithelial cells, lens ﬁber cells, and red blood
cells [123–125]. In mouse skeletal muscle, the predominant
Tmod isoform associated with γ-actin in the SR is Tmod3,
whichsharesalocalizationpatternwithγ-actinandnonmus-
cleTMsinanSRmicrodomainattheM-lineandﬂankingthe
Z-line [63] (Figures 2 and 3). Tmod3 appears to be tethered
to the SR at the M-line via an interaction with small ankyrin
1.5 (sAnk1.5) [63], a 17-kDa splice variant of ankyrin-R
(ankyrin 1) with a hydrophobic transmembrane segment
[126–128]. The Tmod3/sAnk1.5 complex in the SR contains
γ-actin and nonmuscle TMs (TM5NM1 and TM4) and
is not associated with sarco/endoplasmic reticulum Ca2+-
ATPase or the ryanodine receptor. Instead, Tmod3-capped
γ-actin ﬁlaments may be components of an SR-to-myoﬁbril10 Journal of Biomedicine and Biotechnology
mechanical linking system, the best-characterized compo-
nent of which is the giant (∼720kDa) protein obscurin,
which links sAnk1.5 in the SR to myomesin and titin in
the M-line [129, 130]. The mouse skeletal muscle SR also
contains a minor Z-line-ﬂanking microdomain containing
Tmod1 and Tmod4, which, based on its localization pattern,
may be associated with the SR or T-tubule system [63].
Counterintuitively, deletion of Tmod1 in mice enables
the study of the functional signiﬁcance of Tmod3 in the
SR, because Tmod3 vacates the SR and moves to the thin
ﬁlament pointed ends in adult Tmod1-null muscle [31, 63].
Thus,Tmod1deletionappearstobeaproxyfor“conditional”
Tmod3 deletion from the SR. In this scenario, loss of Tmod3
from the SR selectively destabilizes its associated complex
with sAnk1.5 and perturbs the localizations of γ-actin,
nonmuscle TMs, and sAnk1.5. This leads to aberrant SR
swelling,depressed Ca2+ release,and myoﬁbril misalignment
[63]. Notably, previously identiﬁed SR-associated membrane
skeleton proteins, β2-spectrin and ankyrin-B, which are
involved in targeting SR-associated ion channels in the
heart [131–134], are not associated with the Tmod3/sAnk1.5
complex, and are not perturbed by deletion of Tmod1 and
redistribution of Tmod3 from the SR to the thin ﬁlament
pointed ends [63]. This suggests that Tmod3, γ-actin, and
nonmuscle TMs deﬁne a novel membrane skeleton-like net-
work associated with sAnk1.5 in the SR, which mechanically
stabilizes the SR, facilitates SR Ca2+ release, and provides
connectivity among adjacent myoﬁbrils via linkages between
sAnk1.5 and obscurin [63, 130, 135]. Certainly, creation of
a Tmod3-null mouse is required to demonstrate rigorously
that the SR phenotype is indeed due to the redistribution
of Tmod3 from the SR to the thin ﬁlament pointed ends,
rather than due to deletion of Tmod1 from a diﬀerent
SR compartment or from the T-tubules. In addition, by
analogy to nebulin-null mice [136], it is also possible that
eﬀects of Tmod1 deletion on actin pointed-end dynamics
and thin ﬁlament stability may lead to secondary eﬀects on
SR Ca2+ handling (see Section 7). Future work needs to
focus on the molecular architecture of the SR-associated γ-
actin cytoskeletal network at the Z- and M-lines and the
mechanisms that drive isoform-speciﬁc sorting of actins and
Tmods in striated muscle. Furthermore, whether Tmod3
plays a role in the cardiac SR analogous to its role in the
skeletal muscle SR remains to be determined. It is tempting
to speculate that the upregulation of γ-actin that occurs in
muscular dystrophy might inﬂuence Ca2+ handling in the
SR in addition to its better-characterized role in binding
to dystrophin and mechanically fortifying the sarcolemma;
such a model would be consistent with evidence implicating
aberrant SR Ca2+ handling in the pathogenesis of muscular
dystrophy [137–139].
7. PotentialRelevance of Tmods to
HereditaryMuscleDiseases
A persistent question is whether or not Tmods are directly
involved in the pathogenesis of human nemaline myopathy,
askeletalmusclewastingdiseasethataﬄicts ∼1:50,000indi-
viduals, arises from mutations in thin ﬁlament-associated
proteins, and is marked by the presence of aberrant actin
bundles and so-called “nemaline bodies” consisting of thin
ﬁlament material [140–142]. In human skeletal muscles, a
combination of Tmod1 and Tmod4 caps the pointed ends
of the thin ﬁlaments (D. S. Gokhin and V. M. Fowler,
unpublished data), identical to mouse muscles [31, 63],
and mutations in almost all known thin ﬁlament-associated
proteins, including α-actin (ACTA1), β-a n dγ-TM isoforms
(TPM2 and TPM3), troponin I and T isoforms (TNNI2,
TNNT1,a n dTNNT3), and nebulin (NEB)[ 140–142], have
been found to produce various degrees of hereditary nema-
line myopathy. A nemaline myopathy-linked ADF/coﬁlin
(CFL2) mutation has also been identiﬁed, implying that
aberrant regulation of actin dynamics and turnover in thin
ﬁlaments can lead to muscle pathologies (see Section 2)
[81]. While Tmod1 deletion in mice produces mild muscle
pathologywithdepressedisometricstressproduction,nema-
line bodies are not observed, most likely due to structural
compensation by Tmod3, which caps the thin ﬁlament
pointed ends with Tmod4 in the absence of Tmod1, thus
preserving thin ﬁlament stability and length regulation [31,
63]. Nevertheless, it is possible that weakened and more
dynamicTmod3/Tmod4bindingtothethinﬁlamentpointed
ends may alter TM-troponin regulation of actomyosin cross-
bridge activity and thereby contribute to muscle weakness
[31]; similar changes in productive actomyosin crossbridge
formation have been observed in nebulin-null mice as well
as in human nemaline myopathy [143–147]. However, the
phenotype of Tmod1-null skeletal muscle is distinct from
classical nemaline myopathy, because Tmod1-null muscle is
not overtly myopathic [31], and Tmod3 translocation from
the SR to thin ﬁlament pointed ends is accompanied by
SR defects and myoﬁbril misalignment that can account for
the muscle weakness [63]. Furthermore, no Tmod mutations
have yet been identiﬁed as a basis for nemaline myopathy.
Clearly, Tmod perturbations can cause muscle pathology
in mice, and mutations in the proteins that comprise
the Tmod-associated thin ﬁlament structures (i.e., disease
“hotspots”) in skeletal muscle cause hereditary diseases in
humans. However, despite Tmods being integral structural
components of thin ﬁlaments, they are, thus far, conspic-
uously absent from the list of thin ﬁlament proteins that
cause nemaline myopathy. Indeed, Tmods appear to be
the only thin ﬁlament proteins with no as-yet-identiﬁed
mutations that cause nemaline myopathy. Why might this be
the case? The most likely answer is that Tmods are essential
genes in humans. Deletion of Tmod1 is embryonic lethal in
mice due to defects in cardiac looping morphogenesis and
myoﬁbrilassembly,resultinginaborteddevelopmentearlyin
embryogenesis[59,68];indeed,studiesofTmod1’sfunctions
in noncardiac tissues in vivo require cardiac-speciﬁc rescue
of Tmod1 to permit animal development and progression
into adulthood [31, 63, 65, 124, 125]. Thus, it would be
reasonable to predict that wholesale Tmod1 deletion would
be lethal in humans as well. However, it is conceivable
that Tmod1 mutations resulting in milder Tmod1 functional
deﬁcits or partially reduced Tmod1 levels could be associated
with hereditary myopathies in humans. Tmod4 mutations
are another possibility; in humans, Tmod4 is only presentJournal of Biomedicine and Biotechnology 11
in skeletal muscle [20, 21] and is a good candidate gene for
skeletal muscle disease, because its perturbation would not
be expected to cause cardiac defects. Nonetheless, the most
probable reason that no myopathy-linked Tmod1 or Tmod4
mutations have yet been identiﬁed is compensation by other
Tmod isoforms (i.e., Tmod3), as shown in mice [31, 63].
Additionalstudiesontheindividualswhoarediagnosedwith
a nemaline myopathy of unknown genetic etiology [140]a r e
required for the identiﬁcation of putative Tmod mutations
associated with nemaline myopathy or other skeletal muscle
myopathies.
In addition to the potential involvement of Tmod1 and
Tmod4cappingofα-actinthinﬁlamentsinnemalinemyopa-
thy, putative Tmod3 capping of γ-actin ﬁlaments in the SR
[63] may play a role in muscular dystrophy. Tmod3 capping
of γ-actin ﬁlaments occurs in conjunction with nonmuscle
TM5NM1 and TM4 binding to the sides of γ-actin ﬁla-
ments, which is essential for normal excitation-contraction
coupling, SR function, and maintaining a nondystrophic
condition [148–150]. γ-Actin is dramatically upregulated
in dystrophic muscle [121, 122], but whether this aﬀects
SR structure or function or speciﬁc SR-associated γ-actin-
regulatory proteins (e.g., Tmod3 and nonmuscle TM5NM1
and TM4) remains unknown. Indeed, γ-actin upregulation
without compensatory alterations in the pool of γ-actin-
regulatory proteins may result in uncontrolled γ-actin
polymerization, which may adversely aﬀect the structure,
stability,andfunctionoftheSRand/orsarcolemma.Another
possibilityisthatmusculardystrophy-inducedmisregulation
of γ-actin-regulatory proteins may alter γ-actin turnover in
a manner that is toxic to the muscle cell via mechanisms
involving aberrant Ca2+ handling [137, 138]. It is important
to recognize that such proposals are speculative at this
point. However, given this clinical context, they highlight
the fact that the future of the “Tmods in muscle” ﬁeld lies
in dissecting the molecular mechanisms by which Tmods
cap and stabilize actin ﬁlaments during development and
disease, exploring the abilities of Tmods to regulate muscle
physiology and contractility, and uncovering potential links
between Tmod perturbations and muscle pathology.
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